EPISODE · Dec 9, 2025 · 14 MIN
ASH 2025: Ascentage Pharma Chairman & CEO Dajun Yang shares an update on the company's Bcl-2, lisaftcoclax, which was recently approved in China and is in multiple global registration studies
from BiotechTV - News · host BiotechTV
The therapy has shown single agent efficacy in patients who are refractory to BTKs. Plus, and update on global studies of the BCR-ABU/KIT, olverembatinib, and highlighting Ascentage's EED inhibitor.
Embed this episode
Ready to play
ASH 2025: Ascentage Pharma Chairman & CEO Dajun Yang shares an update on the company's Bcl-2, lisaftcoclax, which was recently approved in China and is in multiple global registration studies
0:00
14:13
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 14 minutes long.
When was this BiotechTV - News episode published?
This episode was published on December 9, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!